Adapted from Product Monograph
PrREXULTI® is taken orally, with or without food
- No additional benefit was demonstrated at doses greater than 2 mg/day.
- Dosage increases should occur at weekly intervals based on the patient’s clinical response and tolerability. Periodically reassess to determine the continued need and appropriate dose for treatment.
- The required length of adjunctive treatment with REXULTI is unknown. When prescribed as an adjunct to antidepressants in the treatment of MDD, REXULTI should be used for the shortest period of time that is clinically indicated.
Special dosing considerations
Hepatic impairment
For patients with moderate to severe hepatic impairment, the maximum recommended dose is 1.25 mg/day.
Renal impairment
For patients with moderate, severe or end-stage renal impairment, the maximum recommended dose is 1.25 mg/day.
CYP isozymes
Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers, and in patients who are taking concomitant strong CYP3A4 inhibitors, strong/moderate CYP2D6 inhibitors with strong/moderate CYP3A4 inhibitors or strong CYP3A4 inducers.
Cardiovascular conditions
Dosage adjustments are recommended in patients at risk of orthostatic hypotension. Particular care should be exercised in patients with QTc prolongation, which may lead to ventricular arrhythmias including torsade de pointes.
Hepatic impairment
For patients with moderate to severe hepatic impairment, the maximum recommended dose is 1.25 mg/day.
CYP isozymes
Dosage adjustments are recommended in patients who are known CYP2D6 poor metabolizers, and in patients who are taking concomitant strong CYP3A4 inhibitors, strong/moderate CYP2D6 inhibitors with strong/moderate CYP3A4 inhibitors or strong CYP3A4 inducers.
Renal impairment
For patients with moderate, severe or end-stage renal impairment, the maximum recommended dose is 1.25 mg/day.
Cardiovascular conditions
Dosage adjustments are recommended in patients at risk of orthostatic hypotension. Particular care should be exercised in patients with QTc prolongation, which may lead to ventricular arrhythmias including torsade de pointes.
Please consult the Product Monograph for full dosing information.
Reference: 1. REXULTI Product Monograph. Otsuka Pharmaceutical Co., Ltd.
